Business Wire

CIRIUM

16.12.2021 09:02:12 CET | Business Wire | Press release

Share
45,000 More-Fuel-Efficient Aircraft, Worth US$2.9 Trillion, Predicted to Be Delivered By 2040

The new 2021 Cirium Fleet Forecast reveals that US$2.9 trillion is expected to be spent on approximately 45,000 new and more-fuel-efficient aircraft over the next 20 years.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211215005489/en/

Published by Ascend by Cirium, the consultancy arm of aviation analytics firm Cirium , the Cirium Fleet Forecast predicts that 20-year aircraft deliveries globally by 2040 will be 4% higher than previously predicted a year ago.

This outlines a positive outlook for the aviation industry and its recovery from the COVID-19 pandemic.

COVID-19 significantly affected air travel and so aircraft deliveries, with a 43% reduction during 2020 — 600 fewer aircraft — before the recovery in 2021, albeit still 25% below the 2019 level.

As vaccination programs have been increasing globally, air travel is reopening resulting in 300 more aircraft deliveries in 2021 — despite the issues surrounding Boeing’s 787.

Rob Morris, Global Head of Consultancy at Ascend by Cirium said: “The 2021 Cirium Fleet Forecast provides an optimistic long-term forecast for aviation which sees the industry return — although structurally differently to before — to more traditional growth paths beyond 2024. Passenger traffic is predicted to grow annually at 3.7% and so the global passenger fleet will be required to increase by almost 22,000 aircraft.”

“If this forecast is realised that would take the global passenger fleet to some 47,200 aircraft by the end of 2040. The aircraft deliveries that are predicted will not only meet the rising traffic demands but will also replace older less-fuel-efficient aircraft.”

China will receive the most deliveries

The number of aircraft deliveries will vary from airline region to region, with Asian markets expected to be the engine for growth.

China is forecast to have the highest passenger traffic growth rate at over 6% — making it the country with the largest amount of deliveries achieving a 20% share.

This is significantly ahead of all other Asia-Pacific countries, which have a combined 22% share in total.

North American airlines are forecast to have 20% share and European carriers to have 17%.

The Middle East is estimated to take a 7% share, but in value terms it will be 11% by virtue of the high number of twin-aisle aircraft deliveries.

Latin America mirrors that of the Middle East with a 7% share, followed by Russia and CIS on 4% and Africa at 3%.

Majority of deliveries will be single-aisle jets

The Fleet Forecast reveals that single-aisle jets will account for 70% of total aircraft deliveries and 55% of delivery value in the next 20 years.

The core of this US$1.6 trillion market continues to be the 150-seat size aircraft, typified by the Airbus A320neo and Boeing 737 Max 8, which will make up 50% of deliveries.

Popular 180+ seater aircraft, including the A321 neo and B737 Max 10, will take an increasing annual share, with 40% of deliveries over the two decades.

New single-aisle aircraft programs from both Airbus and Boeing are forecast to be developed in the early to mid-2030s.

The US$1.1 trillion twin-aisle aircraft market will focus on B787s and A350s, with ‘mid-sized’ 250-300 seaters taking some 65% of delivery value. The highest capacity markets will be fought over by the A350-1000 and B777-9.

Deliveries in the regional markets are forecast to be worth US$150 billion. Around a third of this figure is for turboprops, led by the 70-seat sector aircraft, with a larger 90-seat size from the 2030s. Future programs include China’s MA700 and an expected new series from Embraer.

Older fleets will be replaced with new generation aircraft

About 80% of the current passenger fleet is forecast to be retired from passenger service between 2021 and 2040.

The replacement of these older aircraft — which have higher fuel burn — with new models, is becoming more important as the industry looks to drive reductions in carbon emissions and focus on sustainability.

Overall, there will be some 19,000 retirements from the end-2020 passenger fleet, in addition to the early phasing out of several relatively young aircraft.

Ascend by Cirium’s analysis forecasts an average economic life of 22 years for single-aisle aircraft and 20 years for twin-aisle aircraft.

Freighters: New builds and conversions are rising

As cargo remains strong, freighter capacity (based on available tonne kilometers) is forecast to grow at 3.3% compared to 2019 and the supply of freighter aircraft is predicted to be around 3,500 aircraft over the next 20 years.

Of this total, 30% are expected to be newbuild freighters and 70% are conversions from passenger to freighter aircraft. Around 1,050 new aircraft are forecast worth US$121 billion.

Passenger-to-freighter conversions are being driven by the growth of e-commerce, which has been boosted by more online shopping during lockdowns.

These conversion programs are focused on newer-generation aircraft types, such as the A321, B737-800, A330 and B777-300ER.

The Cirium Fleet Forecast is an independent outlook of the global commercial passenger and freighter aircraft market, based on the largest data portfolio in aviation and years of expertise.

To download an Executive Summary of the 2021 Cirium Fleet Forecast, click here.

Ends

About Cirium
Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.

For further information please follow Cirium updates on LinkedIn or Twitter or visit www.cirium.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye